ASCO 2014 - Lung Cancer

There are insufficient data evaluating the efficacy of a first-line regimen consisting of an EGFR-TKI plus platinum-based doublet chemotherapy in EGFR-mutant (mut) NSCLC.
Nivolumab (N), a fully human monoclonal antibody that is a PD-1 immune checkpoint inhibitor, has demonstrated efficacy in patients with previously treated advanced NSCLC.
Dacomitinib (D) is an irreversible pan-HER kinase inhibitor that has been shown to be effective in patients with EGFR-activating mutations and in those with EGFR and KRAS wild-type (wt) NSCLC.
There are no reliable data on the first-line treatment with the oral ALK inhibitor crizotinib (C) for advanced NSCLC compared with standard chemotherapy.
Despite advances in therapy of NSCLC represented by EGFR-TKIs, median progression-free survival (PFS) in patients with EGFR-mutation positive (mut) NSCLC is still only about 13 months.
AZD9291 is a third-generation EGFR–tyrosine kinase inhibitor (TKI) that has been shown in preclinical models to be effective against both EGFR-TKI sensitizing and resistance T790M mutations.
Patients with ALK-rearranged (ALK+) NSCLC benefit from therapy with crizotinib, but invariably progress on this therapy. Ceritinib (Cer) is a novel ALK inhibitor (ALKi) that has been shown to be more potent than crizotinib in in vitro and animal models.
Standard therapy for inoperable stage III NSCLC is concurrent chemoradiotherapy (CCRT). The value of consolidation chemotherapy with docetaxel (D) plus cisplatin (C) following definitive CCRT was reported from a multinational, phase 3, randomized trial...
The RADIANT study was a randomized, double-blind, phase 3 trial comparing adjuvant erlotinib (E) versus placebo (PBO) following complete tumor resection (with or without adjuvant chemotherapy) in patients with stage IB-IIIA EGFR-positive NSCLC...
The REVEL study was a randomized, double-blind, phase 3 study of docetaxel (DOC) plus ramucirumab (RAM; a human anti-VEGFR-2 monoclonal antibody) compared with DOC plus placebo (PBO) as second-line therapy for stage IV NSCLC following disease progression after prior platinum-based chemotherapy...
Page 1 of 3
Results 1 - 10 of 21
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology